search
Back to results

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor (SEALS Xpert)

Primary Purpose

Non-muscle Invasive Bladder Cancer, Urinary Biomarker

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Xpert Bladder Cancer Monitor
Flexible cystoscopy (WL/NBI) and urinary cytology
Sponsored by
Jørgen Bjerggaard Jensen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Non-muscle Invasive Bladder Cancer focused on measuring Flexible cystoscopy, Xpert Bladder Cancer Monitor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years of age at the time of signing the Informed Consent Form
  • Ability to understand the Participant Information sheet orally and in writing
  • Signed Informed Consent Form
  • Is, according to the investigator's judgement, able to comply with the trial protocol
  • Previously diagnosed with high grade NMIBC Recurrence free at the time of inclusion detected by flexible cystoscopy

Exclusion Criteria:

  • History of any upper urinary tract tumor regardless of grade and stage within the last 5 years prior to randomization
  • T1 tumor where re-resection has not been performed
  • CIS or invasive tumor within 3 months before randomization

Sites / Locations

  • Hospital of West Jutland
  • Zealand University Hospital
  • Aarhus University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control

Intervention

Arm Description

Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.

Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.

Outcomes

Primary Outcome Measures

Recurrence-free survival
Time from inclusion to detection of recurrence of bladder cancer.

Secondary Outcome Measures

Full Information

First Posted
September 19, 2019
Last Updated
May 30, 2023
Sponsor
Jørgen Bjerggaard Jensen
Collaborators
Cepheid
search

1. Study Identification

Unique Protocol Identification Number
NCT04100733
Brief Title
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
Acronym
SEALS Xpert
Official Title
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 1, 2019 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jørgen Bjerggaard Jensen
Collaborators
Cepheid

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study aims to evaluate the potential clinical impact of a highly sensitive urinary marker, the Xpert Bladder Cancer Monitor, regarding possible reduction in number of flexible cystoscopies in an outpatient setting without decreasing recurrence-free survival or increasing risk of progression.
Detailed Description
Epidemiology and treatment Bladder cancer is the 12th most diagnosed cancer worldwide with an incidence of approximately 550 000 new cases each year.1 A majority of the tumors are characterized as non-muscle invasive bladder cancer (NMIBC), meaning stage T1 according to the 2016 TNM-classification.2 Treatment of primary NMIBC is transurethral resection of the bladder (TUR-B) and treatment of recurring NMIBC is repeated TUR-B and often adjuvant instillation therapy with either Mitomycin C or Bacillus Calmette-Geerin (BCG) according to the histology of the tumor. NMIBC-tumors are graded into high grade (HG) and low grade (LG) according to the histological characteristics of their TUR-B specimen. Generally, intravesical Mitomycin C is recommended to treat LG tumors and intravesical BCG is recommended for treating HG tumors.3,4. Follow-up schedules based on risk of recurrence. The histological grade, number of tumors, tumor size, T-stage, recurrence-rate and presence of carcinoma in situ (CIS) is used to estimate risk of recurrence according to the EORTC-scoring system. Based on the risk stratification, different follow-up schedules after initial TUR-B are planned. High risk tumors are followed-up with flexible cystoscopy and urinary cytology every four months until two recurrence-free years, whereas low and intermediate risk tumors are followed utilizing the 4-8-12 model where intervals between follow up are increased for patients without recurrence until 5 disease-free years.3 The evidence behind these follow-up schedules is not based on high level evidence and research but rather on tradition and 'clinical experience'. Clinical challenge of current follow-up schedules The majority of patients with HG tumors will have recurrence despite treatment, especially within the two first years after diagnosis. Moreover, many patients will receive lifelong follow-up cystoscopy and urinary cytology tests. Follow-up schedules are costly due to many visits at the hospital for flexible cystoscopy, urinary cytology, and treatment. A micro-costing analysis performed by the Urological Research Unit at Aarhus University Hospital prior to initiation of the current study, has shown that the total expense in relation to flexible cystoscopy in the outpatient clinic is approximately 315 EUR per examination (Appendix 1). Equally important to frequency and cost of follow-up, every follow-up visit is associated with patient discomfort, pain, risk of infections, and strictures of the urethra.6 Each cystoscopy carries a 15% risk of complications. Nearly 1,500 cystoscopies are carried out in HG patients in Central Denmark Region each year, resulting in approximately 240 complications each year, with cystitis being the most common complication. Furthermore, flexible cystoscopy is not always reliable in terms of diagnosing recurrences and CIS.7-9 Urinary biomarkers A proposed alternative to flexible cystoscopy in the detection of recurrent NMBIC is non-invasive molecular urinary markers that detect mRNA, protein or DNA from selected genes relevant for bladder cancer in urine samples. Several studies have been prospectively validated and shown high sensitivity and specificity for urinary markers.10,11 Recently, the Xpert Bladder Cancer Monitor test was shown by Valenberg et al.12 to have a sensitivity of 83% and specificity of 76% for HG disease and similarly D'Elia et al.13 showed a specificity of 77% and sensitivity of 46% for a cohort of mainly LG patients. However, studies have until now focused mainly on detection of NMIBC in patients with incident tumors, which are most often larger and more easily diagnosed with urinary biomarkers than recurrences.14 To our knowledge, no studies have so far substituted cystoscopies for urinary biomarkers in a randomized controlled setting. Thus, the need for high level evidence regarding the use of urinary biomarkers for surveillance of NMIBC is still there.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-muscle Invasive Bladder Cancer, Urinary Biomarker
Keywords
Flexible cystoscopy, Xpert Bladder Cancer Monitor

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
392 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Active Comparator
Arm Description
Study subjects will cohere to current clinical guidelines for follow-up regimes of HG NMIBC with flexible cystoscopy and cytology every four months for a period of two years.
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Patients in the interventional arm will be followed at 4, 8, 16 and 20 months after inclusion with Xpert Bladder Cancer Monitor-test (and urinary cytology) instead of flexible cystoscopy.
Intervention Type
Diagnostic Test
Intervention Name(s)
Xpert Bladder Cancer Monitor
Intervention Description
Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
Intervention Type
Diagnostic Test
Intervention Name(s)
Flexible cystoscopy (WL/NBI) and urinary cytology
Intervention Description
Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
Primary Outcome Measure Information:
Title
Recurrence-free survival
Description
Time from inclusion to detection of recurrence of bladder cancer.
Time Frame
2 years follow-up per patient

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years of age at the time of signing the Informed Consent Form Ability to understand the Participant Information sheet orally and in writing Signed Informed Consent Form Is, according to the investigator's judgement, able to comply with the trial protocol Previously diagnosed with high grade NMIBC Recurrence free at the time of inclusion detected by flexible cystoscopy Exclusion Criteria: History of any upper urinary tract tumor regardless of grade and stage within the last 5 years prior to randomization T1 tumor where re-resection has not been performed CIS or invasive tumor within 3 months before randomization
Facility Information:
Facility Name
Hospital of West Jutland
City
Holstebro
State/Province
Danmark
ZIP/Postal Code
7500
Country
Denmark
Facility Name
Zealand University Hospital
City
Roskilde
Country
Denmark
Facility Name
Aarhus University Hospital
City
Århus N
ZIP/Postal Code
8200
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor

We'll reach out to this number within 24 hrs